share_log

Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments

Benzinga Real-time News ·  Oct 27, 2021 00:15
  • Selecta Biosciences Inc (NASDAQ:SELB) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. 
  • The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.
  • Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases.
  • Under the terms of the collaboration, Ginkgo is eligible for upfront R&D fees and milestones, including certain milestone payments in Selecta common stock, clinical and commercial milestone payments of up to $85M in cash.
  • Related: Selecta In-Licenses Rights To IgG Protease Platform.
  • Price Action: SELB shares are up 7.24% at $3.83, and DNA shares are up 6.09% at $15.15 during the market session on the last check Tuesday.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment